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Introduction
Stroke is the leading cause of physical disability and the second leading cause of death in adults (Machado et al. 2013) . Although thrombolytic therapy and neuroendovascular intervention represents an advance for the treatment of acute stroke a large proportion of survivors still struggle with severe disabilities due to the limited time window for these therapies and frequent unsuccessful recanalization (Nakagomi et al. 2015) . There is no definitive therapy that can restore lost brain function (Bang 2009 ). Numerous approaches have been developed to protect the brain from ischemic damage but have limited success in clinical practice (Bang 2009 ).
The microenvironment in the brain infarct area has been shown to influence the effects of neurorestorative therapies in stroke patients (Bang 2017) . Regulating this microenvironment, by controlling chemokine and trophic factors levels, can increase the degree of recovery after stroke (Wang et al. 2007) . Among the milieu of chemicals expressed in the injured tissue, C-X-C chemokine ligand 12 (CXCL12), also known as stromal-derived factor-1 (SDF-1) and its receptor CXCR4, are potential candidates to modulate the microenvironment in the infarcted brain (Shyu et al. 2008; Wang et al. 2012 ).
CXCL12 is a chemokine known to regulate migration, proliferation, and differentiation of neural stem cells (NSCs) within the developing central nervous system (CNS) (Li et al. 2015) . Previous treatment of stroke with CXCL12 was shown to upregulates the CXCL12/CXCR4 axis and enhances neurogenesis, angiogenesis, and neurological outcome (Shyu et al. 2008; Yoo et al. 2012; Kim et al. 2015) .
However, there is some contradictory results in the literature. CXCL12 was shown to function mainly as an inflammatory initiator during the acute phase of ischemia (Huang et al. 2013; Ruscher et al. 2013) . Pharmacological inhibition of CXCL12 binding to its receptors during the first week after stroke reduced inflammation and neurodegeneration and promoted long-term recovery, without affecting the infarct size (Wu et al. 2017) . Also, higher circulating CXCL12 levels were shown to be linked to poor outcome in stroke patients (Pan et al. 2016; Cheng et al. 2017a ).
The objective of this work is to verify whether CXCL12 delivered to the brain could be beneficial or harmful to stroke outcome. Since chemokines must be delivered locally due to possible dangerous systemic effect, which severely limits their therapeutic use and all previous work used intraparenchymal delivery, we decide to evaluate the intraventricular delivery, in order to facilitate its application in clinical practice.
Material and Methods

Intraventricular injection
Seven-week C57BL/6 female mice were submitted to surgery under anesthesia with intraperitoneal administration of acepromazine (1 mg/Kg, Vetnil, Louveira, São Paulo), xylazine (10 mg/kg, Ceva, São Paulo, Brazil) and ketamine chloridrate (100 mg/kg, Syntec, São Paulo, Brazil). 
RNA extraction and Quantitative PCR (qPCR)
Total RNA was isolated from brain cortex using the Trizol® reagent (Life Technologies, Thermo Fisher, Waltham, EUA), and RNA concentrations were determined using a NanoDrop ND-1000 instrument (Thermo Fisher). Reversetranscriptase reactions were performed with the ImProm-II Reverse Transcription System (Promega, Madison, USA) using 2 μg total RNA. qPCR was performed using Brilliant® II SYBR® Green QPCR Master Mix (Applied Biosystems, Thermo Fisher) and the Mx3000P QPCR System; MxPro qPCR software was used for the analysis (Stratagene, San Diego, CA USA). Primers sequences are shown in Table 1 .
Values are expressed relative to those from the PBS group. For quantitation, target genes were normalized using a reference control gene (HPRT). The threshold cycle (Ct) for the target gene and Ct for the internal control were determined for each sample, and triplicate experiments were performed. The relative expression of mRNA was calculated using the 2 -ΔΔCt method (Livak and Schmittgen 2001) .
Stroke model
Seven-week C57BL/6 female mice were submitted to surgery under anesthesia with intraperitoneal administration of acepromazine (1 mg/Kg), xylazine (10 mg/kg) and ketamine chloridrate (100 mg/kg). Peroperative analgesia was provided by fentanyl (0.05 mg/ Kg). All procedures were approved by CEUA/Unifesp (9745220217).
Permanent distal middle cerebral artery occlusion was performed as previously described (Llovera et al. 2014) . A 1 cm skin incision between the ear and eye was made and the temporal muscle was separated. The middle cerebral artery (MCA) was identified at the transparent skull, in the rostral part of the temporal area, dorsal to the retro-orbital sinus. The bone was thinned out with a drill right above the MCA branch and carefully withdraw. Next, the brains were removed, stained with 1.5% TTC (2,3,5-Triphenyltetrazolium, Alphatec, São José dos Pinhais, Brazil) at room temperature, for 20 min and immersed in 4% PFA for 24 h. To estimate the amount of cerebral tissue lost after stroke, the brains were sectioned into 2 mm coronal slices using a manual sectioning block, and the lost tissue area in each slice was determined by subtracting the area of the injured hemisphere from the area of the normal hemisphere using Image J software. The volume of brain tissue lost was determined by the sum of each slice area multiplied by the thickness (2 mm): lost area = Σ (area of contralateral side -area of ipsilateral side) x 2 (Llovera et al. 2014 ). For histological analyses, brains were sectioned into 30 μm coronal slices at −20 °C using a CM 1850 cryostat (Leica, Wetzlar, Germany).
Behavioral assessment
The functional outcomes of the stroke model were evaluated using two different behavioral tests, conducted one day before stroke and 1, 4, and 7 days after injury. 
Fluoro-Jade B
Brain sections were mounted with distilled water onto gelatin coated slides and dried on a slide warmer at 37 °C. The tissue was fully dried within 20 min at which time it was immersed in 100% ethyl alcohol for 3 min followed by a 1 min change in 70% alcohol and a 1 min change in distilled water. The slides were then transferred to a solution of 0.06% potassium permanganate for 15 min. The slides were rinsed for 1 min in distilled water, 3 times, and were then transferred to the 
Statistical analysis
Statistically significant differences were evaluated by Student's T-test or one-way ANOVA followed by Tukey post-test using the GraphPad Prism software version 5.01 (GraphPad Software, USA). Results are expressed as mean ± SEM and were considered significant if p<0.05.
Results
Intraventricular administration of CXCL12 increased CXCR4 and CXCR7 expression in the cerebral cortex
We first evaluated whether CXCL12 intraventricular injection could promote a response in the brain cortex (Figure 1 ). We found that animals who received CXCL12 presented an increase in CXCR4 expression after 24 h ( Figure 1A ) and significant increase in CXCR4 expression after 72 h ( Figure 1B ). CXCR7 expression significantly increased in the first 24 h ( Figure 1C ) and was similar to PBS after 72 h ( Figure 1B ).
Intraventricular CXCL12 reduced infarction volume
Once we confirmed intraventricular delivery produced a cortical response regarding expression of CXCL12 receptors CXCR4 and 7, we evaluated its effect on stroke. We first found that mice receiving CXCL12 have a lower ischemic area confirmed by TTC staining (Figure 2A and B) . Also, animals who received CXCL12 behave better, losing less weight after stroke, in a similar way with Sham group ( Figure 2C) . Although the cylinder test revealed no differences between the groups (Figure 2D ), in the 7 th day post ischemia, animals who received CXCL12 recovery better, presenting fewer falls when walking in the grid ( Figure   2E ).
Intraventricular CXCL12 decreased neuronal degeneration and increased reactive astrocytes in brain ischemia
Our next step was to evaluate the molecular mechanisms involved in stroke response to CXCL12 administration.
We first evaluated neuroprotection by analyzing the presence of degenerating neurons, stained by Fluorojade B, in the ischemic borders ( Figure 3A) . Mice who received CXCL12 presented significantly less neuronal degeneration ( Figure 3B) . Surprisingly, along with less neuronal degeneration we observed an increase of the GFAP infiltrate around the ischemic area in 7 days (Figures 3C and D) . The microglial infiltrate, however, did not change between PBS and CXCL 12 groups ( Figures 3C and E) .
Intraventricular CXCL12 increased neurogenesis but not angiogenesis
Finally, we evaluated neurogenesis and angiogenesis at the lesion site. We found twice as many neuroblasts in CXCL12 treated animals ( Figures 4A and B) , but we did not observe an increase in the number of endothelial cells (Figures 4C   and D) .
Discussion
We chose an intraventricular injection to deliver CXCL12 because stroke is usually an extensive lesion and we wanted CXCL12 to reach all the cortex. If we performed an intraparenchymal injection, CXCL12 would concentrate in a single region and probably not diffuse to the entire lesion. We could overcome this by performing multiple intraparenchymal injections, but then, it would be very difficult to translate the results into clinical practice, due the morbidity induced by the procedure.
Our data support that CXCL12 delivered by intraventricular via was able to increase expression of CXCL12 receptors in brain cortex and exert the neuroprotective effects observed previously in brain ischemia (Shyu et al. 2008; Yoo et al. 2012; Kim et al. 2015) . CXCR4 is found at the membrane of a variety of cells including neurons, astrocytes, microglia, bone marrow-derived cells, and NSCs (Wang et al. 2012 ). CXCL12 and CXCR4 are constitutively expressed in the brain but are up-regulated in the ischemic penumbra regions following ischemic stroke (Cheng et al. 2017b) . CXCL12/CXCR4 is thought to play important roles in multiple processes after ischemic stroke, which include inflammatory response, angiogenesis, and the recruitment of bone marrow-stem cells and NSCs to injury (Kokovay et al. 2010; Yellowley 2013) . Despite this evidence, there is plenty of data in the literature showing that AMD3100, a CXCR4 inhibitor, can improve outcome after stroke, mainly by attenuating inflammatory response (Huang et al. 2013; Ruscher et al. 2013; Wu et al. 2017 ).
However, AMD3100 can also bind CXCR7 and function as an allosteric agonist (Kalatskaya et al. 2009 ).
CXCR7 affinity for CXCL12 is almost 10 times higher than for CXCR4 and is more distributed in neurons (Cheng et al. 2017b) . The pathways behind their role are not completely understood. CXCR7 was thought to function as a scavenger receptor that can regulate the extracellular availability of CXCL12, mediating its internalization and subsequent lysosomal degradation (Boldajipour et al. 2008; Sánchez-Alcañiz et al. 2011) . Clarification of the role of CXCR7 will be required in the future (Cheng et al. 2017b ). However, lack of a commercial CXCR7 antagonist difficult this process.
We found that intraventricular CXCL12 decreased degenerating neurons along ischemic area. In fact, in brain development, CXCL12 was find to control neuronal surviving and inhibiting apoptosis (Khan et al. 2008) . Another interesting finding was the increased number of reactive astrocytes in the perilesional area.
Astrocytes are commonly thought to be involved in negative responses through glial scar formation and inhibition of axonal regeneration (Silver et al. 2014) . But new data describe that astrocytes appear to possess a high potential for regeneration and neuroprotection following stroke (Sofroniew and Vinters 2010; Becerra-Calixto and Cardona-Gómez 2017; Teh et al. 2017) . Astrocytes are involved in a large number of key processes essentials to keep integrity of the nervous system, such as regulating the vascular tone, removing excess glutamate in synaptic cleft and preventing excitotoxicity, releasing neurotrophic factors and antioxidants and promoting synaptogenesis (López-Valdés et al. 2014 ). Many studies have suggested that after cerebral ischemia the astrocytes are able to de-differentiate into NSCs and provide a new source of neurons at the lesion site (Magnusson and Frisén 2016) . To our knowledge, the increase in reactive astrocytes in response to CXCL12 have not been reported.
Our most disappointing data was the lack of increased angiogenesis in response to CXCL12 in contrast to what was previously described in the literature. One possible explanation for this is that most studies evaluated angiogenesis after a longer time period, usually 2 to 5 weeks, whereas we used a 7-day end-point (Shyu et al. 2008; Li et al. 2018 ).
Conclusions
Intraventricular administration of CXCL12 was able to produce increased mRNA expression of the receptors CXCR4 and CXCR7 in the cerebral cortex. In stroke, intraventricular administration of CXCL12 decreased mice ischemic area and improved behavioral response. We found CXCL12 was neuroprotective, increased reactive astrogliosis and improved neurogenesis in stroke area. 
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